| Literature DB >> 28534699 |
Laura Gonzalez-Lopez1,2, Nicte S Fajardo-Robledo3, A Miriam Saldaña-Cruz4, Inocente V Moreno-Sandoval1, David Bonilla-Lara1,2, Soraya Zavaleta-Muñiz5, Arnulfo Hernan Nava-Zavala6,7, Paulina Hernandez-Cuervo6, Alberto Rocha-Muñoz8, Norma Alejandra Rodriguez-Jimenez1,9, Maria L Vazquez-Villegas10,11, J Francisco Muñoz-Valle12, Mario Salazar-Paramo9,13, Ernesto G Cardona-Muñoz9, Jorge I Gamez-Nava2,6.
Abstract
Objective To identify correlations of the serum leptin, adiponectin, interleukin-6 (IL-6), and tumor necrosis factor-α (TNF-α) concentrations with the clinical characteristics, presence of spinal syndesmophytes, and body composition in patients with ankylosing spondylitis (AS). Methods Forty-eight patients with AS were compared with 41 sex- and age-matched controls. Assessment included clinical characteristics and the presence of spinal syndesmophytes. The serum leptin, adiponectin, TNF-α, and IL-6 concentrations were determined. Body composition was evaluated using dual-energy X-ray absorptiometry. Results Patients with AS and controls had similar fat mass and lean mass. Patients with AS had higher serum TNF-α and leptin concentrations than controls (52.3 vs. 1.5 pg/mL and 17.2 vs. 9.0 µg/mL, respectively). The IL-6 and adiponectin concentrations were not significantly different between the two groups. Patients with syndesmophytes had higher leptin concentrations than those without syndesmophytes (22.1 vs. 10.9 µg/mL); this difference remained after adjustment for the body mass index. Conclusion Elevated leptin concentrations are associated with spinal radiographic damage in patients with AS and can serve as a biomarker. Future studies should evaluate whether leptin might be a potential target for treatments to avoid structural damage.Entities:
Keywords: Ankylosing spondylitis; adiponectin; body composition; interleukin-6; leptin; syndesmophytes; tumor necrosis factor-α
Mesh:
Substances:
Year: 2017 PMID: 28534699 PMCID: PMC5536407 DOI: 10.1177/0300060517708693
Source DB: PubMed Journal: J Int Med Res ISSN: 0300-0605 Impact factor: 1.671
Characteristics of patients with ankylosing spondylitis.
| Features | Patients (n = 48) |
|---|---|
| Male sex | 30 (63) |
| Disease duration (years) | 9.4 ± 7.3 |
| Disease activity, patient (VAS) | 5.3 ± 3.0 |
| Disease activity, physician (VAS) | 4.1 ± 3.0 |
| BASDAI score | 5.2 ± 2.4 |
| BASFI score | 4.2 ± 2.6 |
| Occiput-to-wall distance (cm) | 3.2 ± 5.5 |
| Tragus-to-wall distance (cm) | 13.5 ± 5.4 |
| Chest expansion | 3.7 ± 1.5 |
| Finger-to-floor distance (cm) | 23.7 ± 17.2 |
| Inter-malleolar distance (cm) | 80.3 ± 28.1 |
| Lumbar flexion (Schober test) (cm) | 3.8 ± 1.9 |
| Treatment | |
| DC-ART synthetics | 45 (94) |
| Sulfasalazine | 29 (60) |
| Methotrexate | 28 (58) |
| Others | 17 (35) |
| Anti-TNF agents | 14 (29) |
| Etanercept | 8 (17) |
| Infliximab | 6 (13) |
| Adalimumab | 1 (2) |
| Glucocorticoids | 7 (15) |
Data are presented as n (%) or mean ± standard deviation. VAS: visual analog scale, BASDAI: Bath Ankylosing Spondylitis Disease Activity Index, BASFI: Bath Ankylosing Spondylitis Functional Index, DC-ART: disease-controlling antirheumatic therapy, TNF: tumor necrosis factor
Comparison of clinical characteristics, adipokines, and cytokines between patients and controls.
| Features | Patients (n = 48) | Controls (n = 41) |
|
|---|---|---|---|
| Male sex | 30 (63) | 27 (66) | 0.74 |
| Salaried employment | 23 (48) | 34 (83) | 0.001 |
| Age (years) | 44.3 ± 11.4 | 46.2 ± 10.7 | 0.44 |
| Height (cm) | 164.6 ± 8.9 | 166.4 ± 10.0 | 0.36 |
| Weight (kg) | 73.9 ± 13.0 | 75.8 ± 13.5 | 0.50 |
| BMI (kg/m2) | 26.9 ± 4.4 | 27.5 ± 4.3 | 0.53 |
| Fat mass (g) | 25.5 ± 8.0 | 25.2 ± 8.5 | 0.86 |
| Lean mass (g) | 43.9 ± 8.8 | 47.5 ± 12.3 | 0.11 |
| Leptin (µg/mL) | 17.2 ± 6.4 | 9.0 ± 7.1 | 0.05 |
| Adiponectin (µg/mL) | 9.1 ± 4.1 | 9.3 ± 4.7 | 0.77 |
| TNF-α (pg/mL) | 52.3 ± 140.6 | 1.5 ± 8.3 | 0.01 |
| IL-6 (pg/mL) | 4.2 ± 9.0 | 1.6 ± 3.3 | 0.08 |
Data are presented as n (%) or mean ± standard deviation. BMI: body mass index, TNF-α: tumor necrosis factor-α, IL-6: interleukin-6. Proportions were compared with the chi-square test. Means were compared with the unpaired Student’s t-test.
Comparisons between patients with ankylosing spondylitis with and without syndesmophytes.
| Features | With syndesmophytes (n = 27) | Without syndesmophytes (n = 21) |
|
|---|---|---|---|
| Male sex | 14 (51.9) | 16 (76.2) | 0.13 |
| Age (years) | 44.3 ± 11.4 | 36.7 ± 10.5 | <0.001 |
| Disease duration (years) | 10.2 ± 8.1 | 8.3 ± 6.3 | 0.37 |
| BMI (kg/m2) | 27.83 ± 4.37 | 25.66 ± 4.11 | 0.08 |
| Fat mass (g) | 27.8 ± 7.4 | 22.8 ± 7.4 | 0.03 |
| BASDAI score | 5.2 ± 2.4 | 5.2 ± 2.5 | 0.98 |
| BASFI score | 4.3 ± 2.8 | 4.2 ± 2.6 | 0.95 |
| Finger-to-floor distance (cm) | 28.2 ± 17.5 | 17.8 ± 15.2 | 0.03 |
| Intermalleolar distance (cm) | 73.3 ± 25.3 | 89.2 ± 29.5 | 0.05 |
| Lumbar flexion (Schober test) (cm) | 3.2 ± 2.0 | 4.5 ± 1.7 | 0.02 |
| Leptin (µg/mL) | 22.1 ± 19.8 | 10.9 ± 6.9 | 0.01 |
| Leptin:BMI ratio | 0.76 ± 0.6 | 0.41 ± 0.2 | 0.009 |
| Adiponectin (µg/mL) | 9.0 ± 4.8 | 9.1 ± 3.1 | 0.93 |
| TNF-α (pg/mL) | 68.2 ± 177.1 | 31.8 ± 70.0 | 0.38 |
| IL-6 (pg/mL) | 5.6 ± 11.4 | 4.0 ± 5.8 | 0.60 |
Data are presented as n (%) or mean ± standard deviation. BMI: body mass index, BASDAI: Bath Ankylosing Spondylitis Disease Activity Index, BASFI: Bath Ankylosing Spondylitis Functional Index, TNF-α: tumor necrosis factor-α, IL-6: interleukin-6. Proportions were compared with the chi-square test. Means were compared with the unpaired Student’s t-test.
Correlation of adipokines and cytokines with clinical features of ankylosing spondylitis.
| Leptin | Leptin:BMI | Adiponectin | TNF-α | IL-6 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
|
|
|
|
|
|
|
|
|
|
| |
| Anthropometric characteristics | ||||||||||
| Weight (kg) | 0.21 | 0.14 | 0.11 | 0.42 | −0.31* | 0.02 | 0.26 | 0.69 | −0.14 | 0.33 |
| Height (cm) | −0.41** | 0.03 | −0.41 | 0.003 | 0.07 | 0.96 | 0.18 | 0.20 | −0.24 | 0.09 |
| BMI (kg/m2) | 0.57** | <0.001 | – | – | −0.31* | 0.02 | 0.17 | 0.22 | 0.01 | 0.90 |
| Fat mass (%) | 0.61** | <0.001 | 0.52 | <0.001 | −0.29* | 0.04 | 0.06 | 0.66 | −0.02 | 0.86 |
| Lean mass (%) | −0.25 | 0.07 | −0.31 | 0.03 | −0.21 | 0.14 | 0.28* | 0.04 | −0.17 | 0.07 |
| Disease characteristics | ||||||||||
| Disease duration (years) | −0.36 | 0.80 | −0.02 | 0.85 | 0.19 | 0.18 | 0.22 | 0.12 | −0.04 | 0.78 |
| Disease activity by patient (years) | −0.54 | 0.71 | −0.04 | 0.78 | 0.21 | 0.14 | 0.15 | 0.28 | 0.17 | 0.22 |
| Disease activity by physician | −0.01 | 0.91 | 0.01 | 0.95 | 0.07 | 0.61 | 0.15 | 0.30 | 0.26 | 0.71 |
| Morning stiffness | −0.33 | 0.82 | 0.01 | 0.97 | 0.17 | 0.23 | 0.09 | 0.53 | 0.16 | 0.26 |
| BASDAI score | 0.32 | 0.83 | 0.05 | 0.74 | 0.53 | 0.72 | −0.21 | 0.88 | 0.10 | 0.48 |
| BASFI score | 0.001 | 1.00 | −0.003 | 0.10 | −0.32 | 0.83 | −0.35 | 0.81 | 0.08 | 0.58 |
| Occiput-to-wall distance | −0.09 | 0.53 | −0.09 | 0.53 | −0.21 | 0.14 | 0.48** | <0.001 | −0.12 | 0.93 |
| Tragus-to-wall distance | −0.31 | 0.83 | −0.02 | 0.84 | −0.29 | 0.04 | 0.52** | <0.001 | −0.00 | 0.99 |
| Chest expansion | −0.07 | 0.59 | −0.18 | 0.90 | 0.07 | 0.59 | −0.05 | 0.69 | 0.06 | 0.64 |
| Finger-to-floor distance | 0.06 | 0.66 | 0.07 | 0.61 | −0.22 | 0.13 | 0.26 | 0.06 | 0.19 | 0.19 |
| Intermalleolar distance | −0.33* | 0.01 | −0.30 | 0.01 | 0.06 | 0.64 | 0.38 | 0.79 | −0.35 | 0.81 |
| Lumbar flexion (Shober test) | −0.001 | 0.99 | −0.02 | 0.87 | 0.04 | 0.74 | −0.28 | 0.05 | −0.18 | 0.19 |
BMI: body mass Index, BASDAI: Bath Ankylosing Spondylitis Disease Activity Index, BASFI: Bath Ankylosing Spondylitis Functional Index, TNF-α: tumor necrosis factor-α, IL-6: interleukin-6